These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24646116)

  • 1. New business models for antibiotic innovation.
    So AD; Shah TA
    Ups J Med Sci; 2014 May; 119(2):176-80. PubMed ID: 24646116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory Incentives for Antibiotic Drug Development: A Review of Recent Proposals.
    Sinha MS; Kesselheim AS
    Bioorg Med Chem; 2016 Dec; 24(24):6446-6451. PubMed ID: 27591793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Financing Pull Mechanisms for Antibiotic-Related Innovation: Opportunities for Europe.
    Årdal C; Lacotte Y; Ploy MC
    Clin Infect Dis; 2020 Nov; 71(8):1994-1999. PubMed ID: 32060511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Encouraging the Development of New Antibiotics: Are Financial Incentives the Right Way Forward? A Systematic Review and Case Study.
    Dutescu IA; Hillier SA
    Infect Drug Resist; 2021; 14():415-434. PubMed ID: 33574682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repairing the broken market for antibiotic innovation.
    Outterson K; Powers JH; Daniel GW; McClellan MB
    Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Learning from our mistakes: using key opportunities to remove the perverse incentives that help drive antibiotic resistance.
    Edwards SE; Morel CM
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):685-692. PubMed ID: 31847613
    [No Abstract]   [Full Text] [Related]  

  • 7. Linking Sustainable Use Policies to Novel Economic Incentives to Stimulate Antibiotic Research and Development.
    Theuretzbacher U; Årdal C; Harbarth S
    Infect Dis Rep; 2017 Mar; 9(1):6836. PubMed ID: 28458797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of drug regulatory authorities and health technology assessment agencies in shaping incentives for antibiotic R&D: a qualitative study.
    Kållberg C; Mathiesen L; Gopinathan U; Salvesen Blix H
    J Pharm Policy Pract; 2023 Mar; 16(1):53. PubMed ID: 36973761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation.
    Towse A; Hoyle CK; Goodall J; Hirsch M; Mestre-Ferrandiz J; Rex JH
    Health Policy; 2017 Oct; 121(10):1025-1030. PubMed ID: 28888660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus.
    Morel CM; Lindahl O; Harbarth S; de Kraker MEA; Edwards S; Hollis A
    J Antibiot (Tokyo); 2020 Jul; 73(7):421-428. PubMed ID: 32203126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline.
    Brogan DM; Mossialos E
    Soc Sci Med; 2016 Feb; 151():167-72. PubMed ID: 26808335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of antibiotics.
    Spellberg B
    Crit Care; 2014 Jun; 18(3):228. PubMed ID: 25043962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Medicare Technology Add-On Payment Could Be Used As A Market Support Mechanism To Accelerate Antibiotic Innovation.
    Gandhi N; Schulman KA
    Health Aff (Millwood); 2021 Dec; 40(12):1926-1934. PubMed ID: 34871069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.
    Rex JH; Outterson K
    Lancet Infect Dis; 2016 Apr; 16(4):500-5. PubMed ID: 27036356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National Facilitators and Barriers to the Implementation of Incentives for Antibiotic Access and Innovation.
    Årdal C; Lacotte Y; Edwards S; Ploy MC; On Behalf Of The European Union Joint Action On Antimicrobial Resistance And Healthcare-Associated Infections Eu-Jamrai
    Antibiotics (Basel); 2021 Jun; 10(6):. PubMed ID: 34205554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic research and development: business as usual?
    Harbarth S; Theuretzbacher U; Hackett J;
    J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel approaches are needed to develop tomorrow's antibacterial therapies.
    Spellberg B; Bartlett J; Wunderink R; Gilbert DN
    Am J Respir Crit Care Med; 2015 Jan; 191(2):135-40. PubMed ID: 25590154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards new business models for R&D for novel antibiotics.
    So AD; Gupta N; Brahmachari SK; Chopra I; Munos B; Nathan C; Outterson K; Paccaud JP; Payne DJ; Peeling RW; Spigelman M; Weigelt J
    Drug Resist Updat; 2011 Apr; 14(2):88-94. PubMed ID: 21439891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model.
    Brogan DM; Mossialos E
    Global Health; 2013 Nov; 9():58. PubMed ID: 24199835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
    Simpkin VL; Renwick MJ; Kelly R; Mossialos E
    J Antibiot (Tokyo); 2017 Dec; 70(12):1087-1096. PubMed ID: 29089600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.